

GI ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS. LAST 12 Month	REGS. LAST 6 Month	REGS. LAST 3 Month	REGS. LAST 30 DAYS	REGS. LAST 7 DAYS	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
SWOG	S1613-mCRC, Adv/Met, TP vs CETIRI	1	Y 0 Screening	130	36	36	34	25	9	1	11/27/2017		119
					36	36	34	25	9	1			
		2	Y 1 Trastuzumab + Pertuzumab 2 Cetuximab + Irinotecan	130	4	4	4	3	2	1	11/27/2017		
					2	2	2	2	1	0			
					6	6	6	5	3	1			
Yes	A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC	1	E Total Registrations		4	4	4	4	0	0	03/23/2018		27
					4	4	4	4	0	0			
	N1048-Rectal,LocalAdv,ChemoRT+/-FOLFOX	1	E Total Registrations		151	32	18	6	2	1	06/05/2013		162
					151	32	18	6	2	1			
	R0848-Panc, Adj, Erlotinib v ChemoRT	1	E Total Registrations		20	0	0	0	0	0	01/24/2011		137
					20	0	0	0	0	0			
		2	E Total Registrations		5	0	0	0	0	0	01/24/2011		
					5	0	0	0	0	0			
No	A021501-Adeno Panc,Borderline Resect,Chemo vs ChemoRT	0	E Total Registrations		18	16	6	3	0	0	05/01/2017		89
					18	16	6	3	0	0			
		1	E Total Registrations		15	13	5	3	0	0	05/01/2017		
					15	13	5	3	0	0			
	EA2142-GI NEC, Adv G3, EP vs TMZ + CAP	1	E Total Registrations		4	3	0	0	0	0	07/14/2016	182	74
					4	3	0	0	0	0			
	NRGGI002-Rectal, Ph II, Sensitization using TNT	1	E Total Registrations		6	4	2	0	0	0	02/21/2017	325	140
					6	4	2	0	0	0			
	NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy	1	E Total Registrations		1	1	1	1	0	0	04/18/2018		18
					1	1	1	1	0	0			

**18-JUN-2018 6:10**  
**GI Open Studies with No Registrations**

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1613 mCRC, Adv/Met, TP vs CETIRI	3 Crossover	09-Oct-17